Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Portfolio Pulse from Benzinga Newsdesk
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) has announced the last patient last visit (LPLV) in the pivotal STRIDE study of mavodelpar in Primary Mitochondrial Myopathies (PMM). The topline data results from the study are expected in December 2023.
October 09, 2023 | 11:51 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reneo Pharmaceuticals has completed the last patient visit in its STRIDE study of mavodelpar. This marks a significant milestone in the study, with topline results expected in December 2023.
The completion of the last patient visit in the STRIDE study is a significant milestone for Reneo Pharmaceuticals. However, the impact on the stock price is uncertain until the topline results are released in December 2023. Therefore, the score is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100